Agreement expands OBT’s access to world-class technologies for its maturing pipeline of therapeutic antibodies in oncology
International biotech company Oxford BioTherapeutics (OBT) and Lonza have signed a non-exclusive licence agreement providing OBT with access to Lonza’s GS Gene Expression System. The agreement covers the research, development and commercial use of the GS System by OBT and contains standard payments and licence fees that have not been disclosed.
The GS Gene Expression System is used for the production of therapeutic recombinant proteins and monoclonal antibodies. The system is characterised by its speed and ease of use. In addition, the higher yielding cell lines provide cost-efficient production of therapeutic proteins.
‘We are delighted to have access to Lonza’s GS Gene Expression SystemM as an addition to our technology portfolio,’ said Tom Boone, who recently joined OBT as senior vice president, protein sciences, following 28 years at Amgen. ‘The speed and ease of use of the GS System will aid the rapid selection of high-producing cell lines and accelerate the production and development of our most promising anticancer agents.’
OBT has a broad pipeline of preclinical antibody programmes directed to novel cancer targets that it has identified using its OGAP proteomic database.